1. Aged <18 years, 2. Pregnant or lactating women, 3. Allergic to the test drug, 4. The underlying disease is very serious, and the expected survival time is less than 6 months (such as advanced malignant tumors), 5. COPD or end-stage lung disease requires home oxygen therapy, 6. Expected survival time does not exceed 48 hours, 7. Participated in other clinical intervention trials in the past 3 months, 8. Suffering from autoimmune diseases, 9. History of organ, bone marrow or hematopoietic stem cell transplant Received radiotherapy and chemotherapy for malignant tumors within 10.6 months, 11. HIV-infected patients or acquired immune deficiency diagnosed within the past year (CD4 T cells <= 200 / mm3), 12. Patients receiving anti-HCV treatment, 13. 90 days with retinal detachment or eye surgery, 14. Permanent blindness in one eye, 15. History of iritis, endophthalmitis, scleritis, or retinitis, 16. The doctor in charge considers it inappropriate to participate in this study.

1. Aged <18 years, 2. Pregnant or lactating women, 3. Allergic to the test drug, 4. The underlying disease is very serious, and the expected survival time is less than 6 months (such as advanced malignant tumors), 5. COPD or end-stage lung disease requires home oxygen therapy, 6. Expected survival time does not exceed 48 hours, 7. Participated in other clinical intervention trials in the past 3 months, 8. Suffering from autoimmune diseases, 9. History of organ, bone marrow or hematopoietic stem cell transplant Received radiotherapy and chemotherapy for malignant tumors within 10.6 months, 11. HIV-infected patients or acquired immune deficiency diagnosed within the past year (CD4 T cells <= 200 / mm3), 12. Patients receiving anti-HCV treatment, 13. 90 days with retinal detachment or eye surgery, 14. Permanent blindness in one eye, 15. History of iritis, endophthalmitis, scleritis, or retinitis, 16. The doctor in charge considers it inappropriate to participate in this study.